Survival and Pathological Outcomes of Neoadjuvant Chemoimmunotherapy Followed by Surgery in Locally Advanced Oral Squamous Cell Carcinoma
Cancer Control · 2026-05 · 33
DOI: 10.1177/10732748261453684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Control, online erschienen am 19.05.2026. Verfasst von Zixia Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Mouth Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The prognosis of advanced oral squamous cell carcinoma (OSCC) remains poor, with a 5-year survival rate below 50%. While immune checkpoint inhibitors have improved outcomes in recurrent or metastatic head and neck squamous cell carcinoma, the efficacy of preoperative chemoimmunotherapy for locally advanced OSCC remains under investigation. This study aimed to evaluate pathological responses and survival outcomes in OSCC patients receiving neoadjuvant chemoimmunotherapy followed by surgery.
Methods
In this retrospective cohort study, 30 patients with stage III–IV OSCC were treated with one of two induction regimens: toripalimab plus gemcitabine and cisplatin, or tislelizumab with nab-paclitaxel, cisplatin, and low-dose radiotherapy. All patients underwent radical resection after two cycles. Pathological response was assessed based on residual viable tumor (RVT) proportion. Radiologic response was evaluated per RECIST 1.1. Survival analysis was performed using Kaplan-Meier methods.
Results
The pathological complete response (pCR) and major pathological response (MPR) rates at the primary site were both 30.0%. Achieving a radiologic partial response was significantly associated with achieving an MPR (P=0.018). With a median follow-up of 28.5 months, the 3-year overall survival (OS) and disease-free survival (DFS) rates were 80.9% and 65.0%. Patients achieving a pPR or better had significantly improved OS (P=0.007) and DFS (P=0.023). Lymph node metastasis, particularly ≥3 positive nodes, was strongly associated with poor survival (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
- Department of Pathology, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
- Department of Radiology, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
ORCID-Profile: Lizhong Liang
Zitieren
APA
Wang, Z., Li, Y., Feng, J., Wu, L., Li, T., Zhu, X., & Liang, L. (2026). Survival and Pathological Outcomes of Neoadjuvant Chemoimmunotherapy Followed by Surgery in Locally Advanced Oral Squamous Cell Carcinoma. Cancer Control, 33. https://doi.org/10.1177/10732748261453684
Vancouver
Wang Z, Li Y, Feng J, Wu L, Li T, Zhu X, et al. Survival and Pathological Outcomes of Neoadjuvant Chemoimmunotherapy Followed by Surgery in Locally Advanced Oral Squamous Cell Carcinoma. Cancer Control. 2026;33. doi:10.1177/10732748261453684
BibTeX
@article{Wang2026,
author = {Wang, Zixia and Li, Yongliang and Feng, Jiaxin and Wu, Lifen and Li, Tong and Zhu, Xinbiao and Liang, Lizhong},
title = {Survival and Pathological Outcomes of Neoadjuvant Chemoimmunotherapy Followed by Surgery in Locally Advanced Oral Squamous Cell Carcinoma},
journal = {Cancer Control},
year = {2026},
volume = {33},
doi = {10.1177/10732748261453684}
}
EUVIMED